Trial reportBritish journal of cancer2013
AIB1 predicts bladder cancer outcome and promotes bladder cancer cell proliferation through AKT and E2F1.
Trial report in British journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Steroid receptor coactivator-3 regulates glucose metabolism in bladder cancer cells through coactivation of hypoxia inducible factor 1α.The Journal of biological chemistry · 2014Trial
- State-of-the-Art Advances of Nanomedicine for Diagnosis and Treatment of Bladder Cancer.Biosensors · 2022Review
- DAB2IP predicts treatment response and prognosis of ESCC patients and modulates its radiosensitivity through enhancing IR-induced activation of the ASK1-JNK pathway.Cancer cell international · 2022Article
- Gender Differences in Urothelial Bladder Cancer: Effects of Natural Killer Lymphocyte Immunity.Journal of clinical medicine · 2021Review
- SRC-3, a Steroid Receptor Coactivator: Implication in Cancer.International journal of molecular sciences · 2021Review
- Hypoxia-induced Downregulation of SRC-3 Suppresses Trophoblastic Invasion and Migration Through Inhibition of the AKT/mTOR Pathway: Implications for the Pathogenesis of Preeclampsia.Scientific reports · 2019Article
- Impact of AIB1 expression on the prognosis of upper tract urothelial carcinoma after radical nephroureterectomy.Cancer biomarkers : section A of Disease markers · 2019Article
- AIB1 predicts tumor response to definitive chemoradiotherapy and prognosis in cervical squamous cell carcinoma.Journal of Cancer · 2019Article
- Overexpression of amplified in breast cancer 1 (AIB1) gene promotes lung adenocarcinoma aggressiveness in vitro and in vivo by upregulating C-X-C motif chemokine receptor 4.Cancer communications (London, England) · 2018Article
- Prognostic value of AIB1 and EIF5A2 in intravesical recurrence after surgery for upper tract urothelial carcinoma.Cancer management and research · 2018Article
- Honokiol inhibits bladder cancer cell invasion through repressing SRC-3 expression and epithelial-mesenchymal transition.Oncology letters · 2017Article
- TRIM14 regulates cell proliferation and invasion in osteosarcoma via promotion of the AKT signaling pathway.Scientific reports · 2017Article
- Identification and validation of AIB1 and EIF5A2 for noninvasive detection of bladder cancer in urine samples.Oncotarget · 2016Article
- Effects of Androgen and Estrogen Receptor Signaling Pathways on Bladder Cancer Initiation and Progression.Bladder cancer (Amsterdam, Netherlands) · 2016Review
- Amplified in Breast Cancer Regulates Transcription and Translation in Breast Cancer Cells.Neoplasia (New York, N.Y.) · 2016Article
- Long non‑coding RNA‑GAS5 acts as a tumor suppressor in bladder transitional cell carcinoma via regulation of chemokine (C‑C motif) ligand 1 expression.Molecular medicine reports · 2016Article
- Histone acetyl transferase GCN5 promotes human hepatocellular carcinoma progression by enhancing AIB1 expression.Cell & bioscience · 2016Article
- Overexpression of HMGB3 protein promotes cell proliferation, migration and is associated with poor prognosis in urinary bladder cancer patients.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe previously demonstrated that AIB1 overexpression is an independent molecular marker for shortened survival of bladder cancer (BC) patients. In this study, we characterised the role and molecular mechanisms of AIB1 in BC tumorigenicity.
methodsAIB1 expression was measured by immunohistochemistry in non-muscle-invasive BC tissue and adjacent normal bladder tissue. In addition, the tumorigenicity of AIB1 was assessed with in vitro and in vivo functional assays.
resultsOverexpression of AIB1 was observed in tissues from 46 out of 146 patients with non-muscle-invasive BC and was an independent predictor for poor progression-free survival. Lentivirus-mediated AIB1 knockdown inhibited cell proliferation both in vitro and in vivo, whereas AIB1 overexpression promoted cell proliferation in vitro. The growth-inhibitory effect induced by AIB1 knockdown was mediated by G1 arrest, which was caused by reduced expression of key cell-cycle regulatory proteins through the AKT pathway and E2F1.
conclusionOur results suggest that AIB1 promotes BC cell proliferation through the AKT pathway and E2F1. Furthermore, AIB1 overexpression predicts tumour progression in patients with non-muscle-invasive BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.